Skip to main content

Advertisement

Table 3 BNCT clinical trials in Japan using epithermal or mixed thermal & epithermal neutron beams for patients with brain tumors

From: Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

Medical institution Neutron source Treatment dates Tumor type & No. of patientsa Boron compound & treatmentb Clinical outcome Ref.
University of Tsukuba, Tsukuba City, Ibaraki, Japan JRR-4, Japan Atomic Energy Agency, Tokai, Ibaraki, Japan 1999-2002 5 GBM BSH 100 mg/kg in 1–1.5 h MeST: 23.2 mos. (GBM) [96]
    4 AA IO-BNCT MeST: 25.9 mos. (AA)  
   1998-2007 7 GBM BSH 5 g in 1 h, IO-BNCT MeST: 23.3 mos. [97]
      2 y OS: 43%  
   1998-2007 8 GBM BSH 5 g in 1 h & BPA 250 mg/kg in 1 h MeST: 27.1 mos. [97]
      2 y OS: 63%  
     BNCT + XRT   
University of Tokushima, Tokushima, Japan JRR-4 or KURR (Kyoto University Research Reactor, Osaka, Japan) 1998-2000 6 GBM BSH 64.9-178.6 mg/kg MeST: 15.5 mos. [98100]
     IO-BNCT 2 y OS: 0%  
   2001-2004 11 GBM BSH 64.9-178.6 mg/kg MeST: 19.5 mos. [98100]
     IO-BNCT 2 y OS: 27%  
   2005-2008 6 GBM BSH 100 mg/kg & BPA 250 mg/kg MeST: 26.2 mos. [98100]
      2 y OS: 50%  
     BNCT + XRT   
Osaka Medical College, Osaka, Japan KURR 2002-2003 10 GBM BSH 5 g & BPA 250 mg/kg in 1 h MeST: 14.5 mos. [101, 102]
      2 y OS: 20%  
   2003-2006 11 GBM BSH 5 g & BPA 700 mg/kg in 6 h MeST: 23.5 mos. [102]
      2 y OS: 27.3%  
     BNCT + XRT   
   2002-2007 19 rGBM BSH 100 mg/kg & BPA 250 mg/kg in 1 h or MeST: 10.8 mos. post BNCT [103]
    2 rAA, 1 rAOA    
     BSH 100 mg/kg & BPA 700 mg/kg in 6 h 2 y OS: 14%  
   2005-2006 7 rMRM BSH 0–5 g RI: 100% [104, 105]
     BPA 500–700 mg/kg in 3–4 h   
  1. aIncluding other disease sites and patients treated off-protocol, the total number of patients treated at some reactors is much greater than reported here, for FiR-1, ~260, for KURR, >107, and for JRR-4, >200 patients. bTreatment is indicated only in cases when it is not solely external beam BNCT.
  2. Abbreviations: r recurrent, GBM glioblastoma multiforme, IC MM intracranial metastatic melanoma, AA anaplastic astrocytoma, MMng malignant meningioma, MC mesenchymal chondrosarcoma, AOA anaplastic oligoastrocytoma, MRM meningioma related malignancy, IO-BNCT intraoperative BNCT, XRT external beam radiation therapy (photons), MeST median survival time, 2 y OS 2 year overall survival, RI radiographic improvement, NA not available.